Serotonin receptor modulators in the treatment of irritable bowel syndrome

References

• American Gastroenterological AssociationThe burden of gastrointestinal diseases2002AGA Press
   Google Scholar
• AtkinsonWLockhartSWhorwellPJAltered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndromeGastroenterology2006130344316401466
   PubMed Web of Science ®Google Scholar
• AviganMJusticeRMackeyACRe: Brandt et al An evidence-based approach to the management of irritable bowel syndrome in North AmericaAm J Gastroenterol200398210514499800
   PubMed Web of Science ®Google Scholar
• BakerDERationale for using serotonergic agents to treat irritable bowel syndromeAm J Health-syst Pharm2005627001315790796
   PubMed Web of Science ®Google Scholar
• BanhHLMacLeanCToppTThe use of tegaserod in critically ill patients with impaired gastric motilityClinical Pharmacology and Therapeutics200577583615961989
   PubMed Web of Science ®Google Scholar
• BradetteMMoennikesHCarterFCilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global studyGastroenterology2004126A42
   PubMed Web of Science ®Google Scholar
• BrinkerADMackeyACPrizontRTegaserod and ischemic colitisNew England Journal of Medicine20043511361415385670
   PubMed Web of Science ®Google Scholar
• CamilleriMChoiMGReview article: irritable bowel syndromeAliment Pharmacol Ther1997113159042970
   PubMed Web of Science ®Google Scholar
• CamilleriMNorthcuttARKongSEfficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialLancet200035510354010744088
   PubMed Web of Science ®Google Scholar
• CamilleriMReview article: tegaserodAlimentary Pharmacology and Therapeutics2001152778911207504
   PubMed Web of Science ®Google Scholar
• CamilleriMCheyWYMayerEAA randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndromeArchives of Internal Medicine200116117334011485506
   PubMed Web of Science ®Google Scholar
• CamilleriMHeadingRCThompsonWGClinical perspectives, mechanisms, diagnosis and management of irritable bowel syndromeAlimentary Pharmacology and Therapeutics20021614073012182741
   PubMed Web of Science ®Google Scholar
• CamilleriMTreating irritable bowel syndrome: overview, perspective and future therapiesBritish Journal of Pharmacology200414112374815037521
   PubMed Web of Science ®Google Scholar
• CamilleriMMcKinzieSFoxJEffect of renzapride on transit in constipation-predominant irritable bowel syndromeClinical Gastroenterology and Hepatology2004289590415476153
   PubMed Web of Science ®Google Scholar
• ChenJJLiZPanHMaintance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transportersJ Neurosci20012163486111487658
   PubMed Web of Science ®Google Scholar
• CheyWDCheyWYHeathATLong-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndromeAmerican Journal of Gastroenterology200499219515555002
   PubMed Web of Science ®Google Scholar
• CheyWDReview article: tegaserod – the global experienceAlimentary Pharmacology and Therapeutics200420Suppl 7151915521850
   PubMed Web of Science ®Google Scholar
• ClemensCHSamsomMVan BergeEffect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteersAlimentary Pharmacology and Therapeutics200216993100211966509
   PubMed Web of Science ®Google Scholar
• CoffinBFarmachidiJPRueeggPTegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjectsAlimentary Pharmacology and Therapeutics2003175778512622767
   PubMed Web of Science ®Google Scholar
• CoremansGClouseRECarterFCilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea predominance (IBS-D)Gastroenterology2004126Suppl 2A643 Abstract
   Google Scholar
• CreedFFernandesLGuthrieENorth of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndromeGastroenterology200312430312557136
   PubMed Web of Science ®Google Scholar
• CremoniniFDelgado-ArosSCamilleriMEfficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trialsNeurogastroenterology and Motility200315798612588472
   PubMed Web of Science ®Google Scholar
• CremoniniFDelgadoArosTalleyNJFunctional dyspepsia: drugs for new (and old) therapeutic targets. Best Practice and Research in ClinicalGastroenterology20041871733
   Web of Science ®Google Scholar
• DegenLMatzingerDMerzMTegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjectsAliment Pharmacol Ther20011517455111683688
   PubMed Web of Science ®Google Scholar
• DrossmanDACorazziariETalleyNJRome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: A multinational consensus2000Degnon Associates
   Google Scholar
• DelvauxMLouvelDMametJPEffect of alosetron on responses to colonic distension in patients with irritable bowel syndromeAlimentary Pharmacology and Therapeutics199812849559768527
   PubMed Web of Science ®Google Scholar
• DiBaiseJKTegaserod-associated ischemic colitisPharmacotherapy200525620515977922
   PubMed Web of Science ®Google Scholar
• DrossmanDACamilleriMMayerEAAGA technical review on irritable bowel syndromeGastroenterology200212321083112454866
   PubMed Web of Science ®Google Scholar
• EvansBWClarkWKMooreDJTegaserod for the treatment of irritable bowel syndromeCochrane Database of Systematic Reviews20041CD003960
   Google Scholar
• FisherRSThistleJLemboATegaserod does not alter fasting or meal-induced biliary tract motilityAmerican Journal of Gastroenterology1999991342915233676
   PubMed Web of Science ®Google Scholar
• FriedMBeglingerCBobaljNGTegaSwiss Study Group. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndromeEuropean Journal of Gastroenterology and Hepatology200517421715756094
   PubMed Web of Science ®Google Scholar
• GershonMDReview article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motilityAlimentary Pharmacology and Therapeutics200420Suppl 731415521849
   PubMed Web of Science ®Google Scholar
• GershonMDNerves, refl exes, and the enteric nervous systemJ Clin Gastroenterol200539S1849315798484
   PubMed Web of Science ®Google Scholar
• GorardDALibbyGWFarthingMJGInfl uence of antidepressants on whole gut and orocaecal transit time in health and irritable bowel syndromeAliment Pharmacol Ther19948159668038347
   PubMed Web of Science ®Google Scholar
• GoyalRKHiranoIMechanisms of disease: the enteric nervous systemNEJM19963341106158598871
   PubMed Web of Science ®Google Scholar
• GriderJRKuemmerleJFJinJG5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/ 5-HT1p receptors on sensory CGRP neuronsAm J Physiol1996270G778828967488
   PubMed Web of Science ®Google Scholar
• HahnBAYanSStrasselsSImpact of irritable bowel syndrome on quality of life and resource use in the United States and United KingdomDigestion19996077819892803
   PubMed Web of Science ®Google Scholar
• HoughtonLAFosterJMWhorwellPJAlosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteersAlimentary Pharmacology and Therapeutics2000147758210848662
   PubMed Web of Science ®Google Scholar
• IrvineEJReview: Tegaserod prompts global relief of symptoms in irritable bowel syndromeACP Journal Club20041414415341464
   PubMedGoogle Scholar
• IshiguchiTItohHIchinoseMGastrointestinal motility and the brain-gut axisDig Endosc200415816
   Google Scholar
• JohansonJFReview article: tegaserod for chronic constipationAlimentary Pharmacology and Therapeutics200420Suppl 720415521851
   PubMed Web of Science ®Google Scholar
• JonesRHHoltmannGRodrigoLAlosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAlimentary Pharmacology and Therapeutics19991314192710571597
   PubMed Web of Science ®Google Scholar
• KammMAMuller-LissnerSTalleyNJTegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational studyAmerican Journal of Gastroenterology20051003627215667494
   PubMed Web of Science ®Google Scholar
• KawanoKMoriTFuLComparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal functionNeurogastroenterology and Motility20051729030115787949
   PubMed Web of Science ®Google Scholar
• KellowJLeeOYChangFYAn Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndromeGut200352671612692051
   PubMed Web of Science ®Google Scholar
• KhoshooVArmsteadCLandryLEffect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndromeAlimentary Pharmacology and Therapeutics200623191616393297
   PubMed Web of Science ®Google Scholar
• KilkensTOCHonigANieuwenhovenMAVAcute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls2004
   Google Scholar
• KozlowskiCMGreenAGrundyDThe 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised ratGut2000464748010716675
   PubMed Web of Science ®Google Scholar
• KuikenSDTytgatGNBoeckxstaensGEThe selective serotonin reuptake inhibitor fl uoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled studyClinical Gastroenterology and Hepatology200312192815017494
   PubMed Web of Science ®Google Scholar
• LacknerJMGudleskiGDZackMMMeasuring health-related quality of life in patients with irritable bowel syndrome: Can less be more?Psychosomatic Medicine2006683122016554399
   PubMed Web of Science ®Google Scholar
• LemboTWrightRABagbyBLotronex Investigator TeamAlosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndromeAmerican Journal of Gastroenterology20019626627011569692
   PubMed Web of Science ®Google Scholar
• Lesbros-PantoflickovaDMichettiPFriedMMeta-analysis: The treatment of irritable bowel syndromeAlimentary Pharmacology and Therapeutics20042012536915606387
   PubMed Web of Science ®Google Scholar
• LevyRLVon KorffMRWhiteheadWECosts of care for irritable bowel syndrome patients in a health maintenance organizationAm J Gastroenterol2001963122911721759
   PubMed Web of Science ®Google Scholar
• MayerEABermanSDerbyshireSWThe effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patientsAlimentary Pharmacology and Therapeutics20021613576612144587
   PubMed Web of Science ®Google Scholar
• MorganrothJRueggPCDunger-BaldaufCTegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effectsAmerican Journal of Gastroenterology2002972321712358251
   PubMed Web of Science ®Google Scholar
• Muller-LissnerSAFumagalliIBardhanKDTegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipationAlimentary Pharmacology and Therapeutics20011516556611564007
   PubMed Web of Science ®Google Scholar
• Muller-LissnerSHoltmannGRueeggPTegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipationAlimentary Pharmacology and Therapeutics200521112015644040
   PubMed Web of Science ®Google Scholar
• NovickJMinerPKrauseRA randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipationAlimentary Pharmacology and Therapeutics20021618778812390096
   PubMed Web of Science ®Google Scholar
• NyhlinHBangCElsborgLA double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndromeScandinavian Journal of Gastroenterology2004391192615000272
   PubMed Web of Science ®Google Scholar
• PratherCMCamilleriMZinsmeisterARTegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndromeGastroenterology2000118463810702196
   PubMed Web of Science ®Google Scholar
• ReillyMCBarghoutVMcBurneyCREffect of tegaserod on work and daily activity in irritable bowel syndrome with constipationAlimentary Pharmacology and Therapeutics2005223738016128674
   PubMed Web of Science ®Google Scholar
• SandlerRSEverhartJEDonowitzMThe burden of selected digestive diseases in the United StatesGastroenterology200212215001111984534
   PubMed Web of Science ®Google Scholar
• SchoenfeldPReview article: the safety profile of tegaserodAlimentary Pharmacology and Therapeutics200420Suppl 7253015521852
   PubMed Web of Science ®Google Scholar
• SmithDGBarghoutVKahlerKHTegaserod treatment for IBS: a model of indirect costsAmerican Journal of Managed Care2005111 SupplS435015926763
   PubMed Web of Science ®Google Scholar
• TabasGBeavesMWangJParoxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trialAmerican Journal of Gastroenterology2004999142015128360
   PubMed Web of Science ®Google Scholar
• TackJBroekaertDFischlerBA controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndromeGut200655109510316401691
   PubMed Web of Science ®Google Scholar
• TalleyNJGabrielSEHarmsenWSMedical costs in community subjects with irritable bowel syndromeGastroenterology19951091736417498636
   PubMed Web of Science ®Google Scholar
• TalleyNJSerotonergic neuroenteric modulatorsLancet20013582061811755632
   PubMed Web of Science ®Google Scholar
• TalleyNJPharmacologic therapy for the irritable bowel syndromeAmerican Journal of Gastroenterology200398750812738451
   PubMed Web of Science ®Google Scholar
• TalleyNJAntidepressants in IBS: are we deluding ourselves?Am J Gastroenterol20049992115128361
   PubMed Web of Science ®Google Scholar
• TraynorKAlosetron use drops dramatically with risk managementAmerican Journal of Health-System Pharmacy20046112101215259746
   PubMed Web of Science ®Google Scholar
• VahediHMeratSRashidioonAThe effect of fl uoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled studyAlimentary Pharmacology and Therapeutics200522381516128675
   PubMed Web of Science ®Google Scholar
• ViramontesBECamilleriMMcKinzieSGender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndromeAmerican Journal of Gastroenterology2001962671611569693
   PubMed Web of Science ®Google Scholar
• WhiteheadWEBurnettCKCookEWImpact of irritable bowel syndrome on quality of lifeDig Dis Sci1996412248538943980
   PubMed Web of Science ®Google Scholar
• WolfeSGCheyWYWashingtonMKTolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patientsAmerican Journal of Gastroenterology2001968031111280555
   PubMed Web of Science ®Google Scholar